CatalystWireBeta

Operational update & investor webinar

In brief · summary, not quotable

GenIP Plc is bringing the operation and management of its Invention Evaluator platform in-house, ending its agreement with Phosphorix Ltd after a three-month transition period. This strategic move is expected to improve profit margins by retaining the full product margin, eliminate monthly fixed fees and per-report charges, enhance product agility through direct control of the development roadmap, and strengthen governance by removing related-party dependencies. The company has also appointed Harin Vaghela as Chief Product Officer to oversee the platform and drive product strategy. GenIP will host an investor webinar on September 24, 2026, to discuss these developments.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your GNIP notes

GenIP plc (AIM: GNIP), a provider of AI-driven services to help research organisations and corporations commercialise their innovations, announces it has given notice on its agreement with Phosphorix Ltd ('Phosphorix') as part of a planned transition to bring full operation and management of the Invention Evaluator platform in-house.

This is a strategically important and positive development for GenIP which will enhance governance, strengthen operational resilience, and accelerate the Company's ability to innovate and scale its technology platform. Following an agreed three-month transition period, during which Phosphorix will continue to provide support services, GenIP will possesses the full internal resource, technical expertise, and leadership required to manage and scale the Invention Evaluator platform independently.

Bringing production of Invention Evaluator in-house delivers clear and immediate operation and financial benefits, including;

  • Improved margins - the Company will retain the full product margin previously shared under the Phosphorix agreement.
  • Cash savings - the monthly fixed fee and per-report charges will no longer apply.
  • Product Agility - direct ownership of the development roadmap enables faster iteration and enhanced scalability.
  • Clearer governance - the removal of related-party dependencies strengthens compliance with the QCA Code and enhances investor confidence.

Appointment of Chief Product Officer

As part of the transition, the Company has appointed Harin Vaghela as Chief Product Officer ('CPO') who will be responsible for managing the entire Invention Evaluator platform in-house as well as driving the Company's product strategy and technology roadmap. Harin brings over 15 years' experience delivering AI-powered enterprise platforms at organizations including Pasabi, LVMH, and Black Swan Data.

Investor Webinar via CMC CapX Spotlight

Melissa Cruz, CEO and Kevin Fitzpatrick, CFO, will host an investor webinar and Q&A session via CMC CapX Spotlight on 24 September 2026 at 17:00 BST.

The webinar is open to all existing and potential shareholders. Questions can be submitted in advance via GenIP@walbrookpr.com or at any time during the live presentation.

Investors can register for free and join the webinar by clicking HERE.

Investors who are not yet registered with CMC CapX Spotlight will be prompted to create a free account to access the session.

A recording of the webinar will be available on the Company website soon after the event.

Melissa Cruz, CEO of GenIP, commented:

"Bringing Invention Evaluator entirely in-house is a logical and commercially beneficial step for GenIP. By internalising our technology stack and reducing third-party dependencies, we expect to improve product margins while gaining greater control over our development roadmap. With the infrastructure and product leadership now in place, we are well positioned to scale our AI-enabled solutions more efficiently and support the next phase of GenIP's growth."

Service Offerings

GenIP operates through two synergistic service lines:

ServiceDescriptionValue Proposition
IP Commercialisation ServicesEnd-to-end engagement to help research organisations commercialise innovationsProvides cost-effective, broad support to achieve our clients' strategic objectives

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

Vision & Strategy

  • Organic Expansion
  • Service Deepening
  • Strategic Acquisitions

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note